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Abstract 
 
Objective: Abdominal aortic aneurysm (AAA) is a permanent dilation of the abdominal 
aorta associated with rupture which frequently results in fatal consequences.  AAA 
tissue is commonly characterized by localized structural deterioration accompanied 
with inflammation, profound accumulation of leukocytes; although the specific function 
of these cells is unknown.  Cilostazol, a phosphodiesterase III (PDEIII) inhibitor, is 
commonly used for patients with peripheral vascular disease or stroke due to its 
anti-inflammatory effect which is vasoprotective effects through its anti-inflammatory 
effect.  In this study, we evaluated the effects of cilostazol on angiotensin II (AngII) 
-induced AAA formation. 
Approach and Results: Male apolipoprotein E deficient mice were fed either normal 
diet or a diet containing cilostazol (0.1% wt/wt).  After 1 week of diet consumption, 
mice were infused with AngII (1,000 ng/kg/min) for 4 weeks. AngII infusion increased 
maximal diameters of abdominal aortas; whereas cilostazol administration 
significantly attenuated dilatation of abdominal aortas thereby reducing AAA incidence.  
Cilostazol also reduced macrophage accumulation, matrix metalloproteinases 
activation, and inflammatory gene expression in the aortic media.  In cultured 
vascular endothelial cells, cilostazol reduced expression of inflammatory cytokines 
and adhesive molecules through activation of the cyclic AMP – protein kinase A 
pathway. 
Conclusions: Cilostazol attenuated AngII-induced AAA formation by its 
anti-inflammatory effect through PDEIII inhibition in the aortic wall.  Cilostazol may be 
a promising new therapeutic option for AAAs.   
 
 
 
Abbreviations; 
AAA  Abdominal aortic aneurysm 
AngII  Angiotensin II 
MCP-1  monocyte chemoattractant protein-1 
PDEIII  phosphodiesterase III 
PKA   protein kinase A  
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Introduction  
 
Abdominal aortic aneurysm (AAA) is a permanent dilation of the abdominal 
aorta with an onset of symptoms that are often insidious until the overt manifestation 
of rupture.  Associated with advanced age, male sex, cigarette smoking, and genetic 
predisposition, AAA is a common disease with a prevalence of 3-5 % in males over 60 
years of age1.  AAA and aortic dissection is the 9th leading cause of death in the 
Population Survey Report from Ministry of Health, Labour and Welfare in Japan, as 
well as countries of the Western world.  Open and endovascular surgical repairs are 
the only available treatments for large AAAs (> 5 cm).  There is no proven medical 
therapy available, particularly for small AAAs2.  The effects of anti-hypertensive and 
anti-dyslipidemic therapies to prevent aneurysm growth and rupture in patients with 
AAA are still controversial 3-5. 
The pathogenesis of AAA is multifactorial with complex interactions between 
MMP driven enzymatic degradation of aortic elastin and damage to medial smooth 
muscle cells.  Loss of smooth muscle cells, elastin degradation medial thinning, 
adventitial hypertrophy, accumulation of inflammatory cells, atherosclerosis and 
thrombi are common pathological characteristics in human AAAs6, 7.  AAA is regarded 
as a chronic inflammatory disease as previous studies have demonstrated 
accumulation of macrophages and lymphocytes in the aortic wall8, and elevated 
plasma concentrations of IL-1β, IL-6, TNF-α, and IFN-γ in AAA patients9, 10. 
Angiotensin II (AngII)-induced AAA is a commonly used model of aneurysm 
formation in mice.  Chronic AngII infusion induces AAA in normo- and hyperlipidemic 
mice, with some succumbing to aneurysm rupture11 12.  Some pathological features 
of this model resemble human AAAs, including medial elastin degradation and 
accumulation of inflammatory cells, including macrophages, and T and B lymphocyte 
cells in the aortic wall.  During the early phase of AngII-induced AAAs, macrophage 
accumulation occurs in the medial and adventitia layers of the suprarenal aorta.  
Macrophage accumulation into the medial layer is often accompanied by disruption of 
elastin fibers7, 13.  Previous studies have demonstrated the roles of inflammation in 
aneurysmal formation in this model as deletion of cyclooxygenase-2, osteopontin, and 
microsomal prostaglandin E synthase-1 attenuated AngII-induced AAA formation14-16.  
Bone marrow-derived monocyte chemoattractant protein-1 (MCP-1) receptor, 
caspase-1-dependent IL-1β production, IL-6 and TNF-α are also involved in formation 
of AngII-induced AAA17-20. 
Cilostazol, a selective inhibitor of phosphodiesterase III (PDEIII), is commonly 
used in clinical practice as an anti-platelet drug for peripheral artery disease and 
stroke.  PDEIII is expressed in platelets, heart, adipose tissue, liver, kidney and 
arterial tissue21-23.   PDEs degrade cAMP synthesized by adenylate cyclase.  By 
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inhibiting PDEIII enzymatic activity, cilostazol increases intracellular cAMP and 
activates protein kinases, including protein kinase A (PKA) and exchange protein 
directly activated by cAMP.  This leads to myriad effects, including vasodilation and 
inhibition of proliferation in the vasculature, inotropic and chronotropic effects in heart, 
anti-restenosis effects in coronary arteries, reduction of triglycerides and increases of 
high-density cholesterol concentration in plasma, in addition to an anti-platelet effect24, 
25.  Previous studies have shown that cilostazol has anti-inflammatory, anti-oxidative 
stress, and anti-proliferative effects on vasculature26-29.  Despite these 
vasoprotective effects, the effect of cilostazol on AAA development remains unknown.  
In this study, we determined the effects of cilostazol on AngII-induced AAAs in apoE 
deficient (apoE -/-) mice.  Our study demonstrated that cilostazol reduced 
inflammatory changes in the aortic wall and attenuated AAA development.  These 
effects are associated with PDEIII inhibition reducing inflammatory properties of 
endothelial cells. 
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Materials and Methods 
 
Mice and Study Protocol:   
Male, 8-12 week-old, apoE -/- mice were purchased from The Jackson 
Laboratory (Bar Harbor, Cat.#2052).  All mice were maintained in a barrier facility, 
and ambient temperature ranged from 20 °C to 24 °C.  Mice were fed diet and water 
ad libitum.  Only male mice were studied because female mice have very low 
incidence of AngII-induced AAA as detailed in an ATVB Council statement30.  
Cilostazol was a generous gift from Otsuka Pharmaceutical Company.  Either vehicle 
or cilostazol-containing (0.1 %wt/wt) diet were started 1 week prior to AngII infusion.  
For aneurysm quantification and histological analysis, saline or AngII (1,000 ng/kg/min, 
Bachem, Cat. #H-1705) were infused via Alzet mini-osmotic pumps (Model 2004, 
Durect Corp) for 28 days.  Mini-osmic pumps were implanted subcutaneously on the 
right flank, as described previously12, 31.  For mRNA and protein (Western blotting 
and gelatin zymography) analyses, AngII or saline was infused into mice for 7 days.  
The experimental protocol was approved by the Ethics Review Committees for Animal 
Experimentation of Okayama University Graduate School of Medicine, Dentistry, and 
Pharmaceutical sciences. 
 
Blood Pressure Measurement:   
Systolic blood pressure and pulse rate were measured by sphygmomanometry 
using a tail cuff system (BP-98A, Softron) following a published protocol32.  
Conscious mice were introduced into a small holder mounted on a thermostatically 
controlled warming plate and maintained at 37°C during measurement.   
 
Lipids Measurements:   
After an overnight fast, blood was obtained by cardiac puncture under 
anesthesia.  Total cholesterol, triglycerides, and high-density lipoprotein-cholesterol 
concentrations were determined in individual plasma samples using commercially 
available enzymatic-based kits (Wako Chemicals Cat #439-17501, #465-56701, 
#432-40201).   
 
Cilostazol Concentrations: 
Mice were fed either control or ciostazol-containing diet for 5 weeks.  For 
systemic cilostazol concentration measurements, blood was obtained during the 
daytime without fasting and plasma was separated.  Cilostazol concentrations were 
measured using high performance liquid chromatography (Otsuka Pharmaceutical 
Company).  
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Quantification of Aneurysms and Atherosclerosis:   
After 28 days of either saline or AngII infusion, mouse aortas were harvested 
for aneurysm and atherosclerosis quantification following the AHA statement on 
atherosclerosis33.  Aortas were perfused with saline by left ventricular puncture and 
were fixed in 10 % formalin overnight.  Adventitial fat was removed and the 
maximum external width of the suprarenal aorta was measured using computerized 
morphometry (Lumina Vision software, Mitani Corp) as described previously34,35.  
Aneurysm was defined as a 50 % increase compared to saline-infused aorta.  In 
saline-infused mice, the mean suprarenal width was 0.87 mm, consequently we 
defined AAA as > 1.30 mm.  Atherosclerosis was quantified on intima on aortic 
arches as % lesion area by en face method as described previously36-38.  
 
Histological Analysis:   
Mouse abdominal aortas were fixed in formalin, embedded in OCT, and were 
sectioned serially at 10 μm thickness.  Verhoeff’s staining was used to examine 
elastin fiber integrity.  Immunoperoxidase staining was performed to examine 
macrophage infiltration and localization of phosphodiesterase III using a CD68 
antibody (SEROTEC, Cat.#MCA1957) and PDE3A antibody (Abcam, Cat.#ab99236) 
respectively.  Reactivity of the antibodies with tissue antigens was detected using 
AEC and ImmPACT AEC HRP Substrate (Vector Laboratories) as described 
previously39,40. 
 
Gelatin Zymography:   
Either control or cilostazol-containing (0.1 %wt/wt) diet were started 1 week 
prior to AngII infusion, and aortas were harvested 1 week after infusions. Proteins 
were extracted from aortas without any distinguishable aneurysms.  Samples were 
resolved under nonreducing condition on a 7.5 % polyacrylamide gel containing 0.1% 
gelatin as a substrate for MMP activity.  
 
Isolation and Culture of Endothelial Cells:   
Aortic endothelial cells were isolated from apoE -/- mice by an explant 
technique as described previously41, 42.  Briefly, under sterile conditions, aortas were 
removed from apoE -/- mice and adventitia removed.  Aortas were cut into 3 
mm-long rings, placed on Matrigel (BD, Cat. #356234), and incubated in EGM-2 
medium (Lonza) supplemented with 10 % FBS.  Once cell outgrowth was observed, 
vessel rings were removed.  The cells were passaged with dispase (BD, Cat. 
#354235) and then plated onto collagen-coated culture dishes.  Subsequent 
passages were performed with 0.25 % trypsin-EDTA, and cells were split in a 1:4 ratio.  
The identification of cells was confirmed by immnostaining for von Willebrand factor. 
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Cell Culture Conditions:    
Endothelial cells isolated from aorta of apoE -/- mice were used for between 
passages 4-6.  After overnight serum starvation, endothelial cells were incubated 
with selected concentrations of cilostazol (0, 1, 10 μM) / H89(Cayman chemical, Cat. 
#130964-39-5) / forskolin (Cell Signalling, Cat. #9803) for 30 min and incubated in the 
presence of TNF-α (1 ng/ml, R&D, Cat. #410-MT) for 24 hours, then media and cells 
were collected.  Medium was used for the MCP-1 ELISA assay.  Cell lysates were 
used for Western blotting and quantitative PCR.    
 
Realtime Polymerase Chain Reaction:  
mRNAs were extracted from aortas or cell lysates using RNeasy Fibrous 
Tissue Mini kits (Qiagen) or RNeasy Mini kits (Qiagen), respectively.  Reverse 
transcription was performed using iScript cDNA synthesis kit (Bio Rad).  PCR 
reactions were performed with an ABI Step One Real-Time PCR System (Applied 
Biosystems) using Fast SYBR Green Real time PCR Mixture (Applied Biosystems).  
Primers for Ccl2/Mcp-1, Il-1β, Cox2, iNos, Spp1, Icam-1, Mmp-2, Mmp-9 and 18s 
were available commercially (Takara Bio Inc.).  Each sample was normalized to 
values for 18s mRNA expression (ΔΔCT method). 
 
Western Blotting:   
Cultured endothelial cells were placed in lysis buffer (Cell Signaling, Cat 
#9803).  Samples were loaded onto 10 % SDS-PAGE and transferred to PVDF 
membrane, immunoblotted with primary antibodies (ICAM-1, R&D, Cat.#AF796 and 
β-actin, Sigma, Cat.#A1978), followed by secondary antibodies conjugated with HRP.  
Bands were detected by use of an enzyme-linked chemiluminesence detection kit 
(Merck Millipore).  The density was quantified with luminescent image analyzer 
(Fujifilm) and normalized to β-actin. 
 
MCP-1 ELISA assay:  
MCP-1 in culture media was quantified with a sandwich ELISA technique using 
the Quantikine Mouse/Rat CCL2/JE/MCP-1 immunoassay kit (R&D, Cat.#EMJ 00) 
according to the manufacturer’s instructions.    
 
Statistics:  
All plot and bar graphs were created with SigmaPlot v11.0 (Systat Software 
Inc.).  All statistical analyses were performed using SigmaStat v3.5, incorporated into 
SigmaPlot v11.0.   Data are presented as mean ± standard errors (SE).  Statistical 
significance between multiple groups was assessed by Two Way analysis of variance 
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(ANOVA) with Holm-Sidak post hoc or One Way ANOVA with Student–Newman-Keuls 
post hoc, One Way ANOVA with Tukey’s post hoc, One Way ANOVA on Ranks with a 
Dunn’s post hoc, where appropriate. Percentage incidence and mortality of AAA were 
analyzed by Fisher’s Exact test. A p value less than 0.05 was considered statistically 
significant. 
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Results 
 
Cilostazol had no effect on body weight, pulse rate, blood pressure and lipid 
concentrations 
Male, 8-12 week-old, apoE -/- mice were fed either control or 
cilostazol-containing (0.1 %wt/wt) diet.  After 1 week of cilostazol administration, 
either saline or AngII (1,000 ng/kg/min) were infused for 28 days.  Plasma cilostazol 
concentrations in mice fed cilostazol-containing diet were 198 ± 10 ng/ml; while being 
undetectable in mice fed a control diet.  AngII infusion had no effect on plasma 
cilostazol concentrations.  The plasma cilostazol concentrations in mice were 
equivalent to plasma concentrations 12 to 24 hours after oral administration of 100 mg 
in humans.  There were no significant differences in body weight and pulse rate in 
saline or AngII infusions among the 4 groups.  As expected, AngII infusion increased 
systolic blood pressure significantly, but there was no difference between the two 
groups (AngII + control diet and AngII + cilostazol containing diet; Supplemental Table 
I).  In addition, cilostazol had no effect on plasma concentrations of total cholesterol, 
triglyceride, and high density lipoprotein-cholesterol in apoE -/- mice during saline or 
AngII infusion (Supplemental Table II). 
 
Cilostazol attenuated formation of AngII-induced AAA but did not influence 
AngII-accelerated atherosclerosis 
To determine the effects of cilostazol on development of AngII-induced AAAs, 
male apoE -/- mice fed control or cilostazol-containing diet were infused with either 
saline or (saline: n = 5, cilostazol: n = 6) AngII for 28 days (AngII: n = 20, AngII + 
cilostazol: n = 17).  No mice died of aneurysm rupture in saline-infused mice.  In the 
AngII + control diet group, 1 mouse died of thoracic aortic aneurysm (TAA) rupture 
and 3 died of AAA rupture.  In the AngII + cilostazol group, 1 mouse died of TAA 
rupture and 2 mice died of AAA rupture.  At the end of study, ex vivo suprarenal aortic 
width was measured (Fig. 1A).  In saline-infused mice, cilostazol had no effect on ex 
vivo suprarenal aortic width (mean width of abdominal aorta: 0.87 ± 0.04 mm in saline 
mice versus 0.88 ± 0.03 mm in cilostazol mice).  AngII infusion significantly 
increased aortic width (mean width of abdominal aorta: 1.94 ± 0.16 mm, Fig. 1A, 
representative photo in Fig. 1B left).  Cilostazol administration attenuated dilatation 
of aortic width and decreased AAA formation (mean width of abdominal aorta: 1.53 ± 
0.17 mm, p = 0.049, Figure1A, representative photo in Fig.1B right).  Based on AAA 
being defined as a > 50 % increase in suprarenal aorta width, the incidence of AAAs 
in AngII-infused mice not administered cilostazol was 79%.  Cilostazol significantly 
decreased the incidence to 43% (p = 0.029, Fig. 1C).  However, there was no 
significant difference in the aortic rupture rate between the AngII infused group 
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(mortality rate: 15% and 11%, respectively, n.s. Fig. 1D).  There were no differences 
in atherosclerotic lesion area as evaluated by en face method among the 4 groups 
(Supplemental figure I). 
  
Cilostazol reduced medial disruption and macrophage infiltration 
To evaluate the histological characteristics of abdominal aortas, we performed 
Verhoeff’s staining on tissue sections from suprarenal aortas.  Pronounced 
disruptions of medial layers were observed in AngII-infused mice;, however, elastin 
fragmentation induced by AngII infusion were markedly reduced in mice consuming 
cilostazol. (Fig. 2D, E, F).  Since it is known that macrophage-mediated inflammation 
plays an important role in AngII-induced AAA formation, we performed 
immunohistochemistry to determine the localization of macrophages in aortas.  
Immunohistochemistry of CD68 revealed increased macrophage accumulation in the 
region of medial disruption in aorta from AngII-infused mice, whereas less 
macrophage infiltration in medial layer was observed in mice consuming cilostazol 
(Fig. 2G, H, I). 
 
Cilostazol reduced matrix metalloprotease activity in the aorta  
Gelatin zymography was performed to detect MMP-2 and MMP-9.  After 7 
days of AngII infusion, aortas without any discernable aneurysms were used for 
gelatin zymography.  Pro-form MMP-2 (65 and 70 kDa), active-form MMP-2 (58 kDa) 
and MMP-9 (92 kDa) were increased by AngII infusion and reduced by cilostazol 
administration (Fig. 3A, B, C). 
 
Cilostazol administration reduced mRNA abundance of inflammatory cytokines 
in aortas 
Gene expression of inflammatory cytokines such as Ccl2/Mcp-1, Il-1β, Cox2, 
and Spp1 were increased significantly in aortas of AngII mice.  Cilostazol 
administration reduced mRNA abundance of these molecules (Fig. 4).  These results 
suggested that cilostazol suppressed inflammation in aortic walls including 
macrophage accumulation in the media, leading to the reduction of dilatation of aortic 
width and incidence of AAAs.   
 
Cilostazol reduced MCP-1 and ICAM-1 expression in aortic endothelial cells  
Since cilostazol decreased AAA formation in our model and is known to inhibit 
PDEIII function, we sought to investigate the site of PDE III expression in developing 
AAAs. We performed immunohistochemistry for PDEIII in the aorta. PDE III localized 
mainly to the intima and partly in media (Supplemental figure II).  Therefore, we 
investigated the effects of cilostazol on aortic endothelial cells. 
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Endothelial cells isolated from aortas of apoE -/- mice were incubated with 
selected concentrations of cilostazol (0, 1, 10 μM) for 30 min, and then incubated with 
TNF-α (1 ng/ml) for 24 hours. mRNA was extracted for real-time PCR.  TNF-α 
elevated Ccl2/Mcp-1 and Icam-1 mRNA expression; while cilostazol suppressed 
mRNA expression of them in a concentration-dependent manner (Fig. 5A). 
Furthermore, cilostazol reduced TNF-α-stimulated Vcam-1 mRNA expression (Fig. 
5B).  In agreement with this endothelial cell mRNA expression, concentrations of 
CCL2/MCP-1 in cultured media were reduced by cilostazol in a 
concentration-dependent manner (Fig. 5C).  By Western blotting, the abundance of 
ICAM-1 was increased during incubation with TNF-α but reduced by cilostazol, as 
expected (Fig. 5D). 
 
Cilostazol exerted protective effects on aortic endothelial cells through PDEIII 
inhibition 
PDEIII inhibition increases intracellular cAMP, and cAMP exerts 
anti-inflammatory effects through the PKA pathway in vascular endothelial cells 43.  
Therefore, we hypothesized that activation of the cAMP-PKA pathway might be the 
target cilostazol during AAA development.  To further elucidate the mechanism, we 
next performed an in vitro study using forskolin, an activator of adenylate cyclase, and 
H89, an inhibitor of protein kinase A.  Endothelial cells were incubated with cilostazol 
(10 μM) or forskolin (10 μM), cilostazol and H89 (10 μM) for 30 min, incubated with 
TNF-α (1 ng/ml) for 24 hours, then mRNA was harvested from cell lysates and 
subjected to real-time PCR.  TNF-α increased mRNA expression of Ccl2/Mcp-1 and 
Icam-1, but they were reduced by cilostazol and forskolin.  Co-incubation of H89 
blunted the effects of cilostazol (Fig.6).  These results demonstrated that cilostazol 
reduced the expression of inflammatory cytokines and adhesive molecules, such as 
CCL2/MCP-1 and ICAM-1, through the cAMP-PKA pathway. 
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Discussion 
 
Chronic infusion of AngII into hyperlipidemic mice consistently induces AAA 
formation. The characteristics of this AAA model include activation of an inflammatory 
response and stimulation of a proteolytic cascade11.  In the present study, we 
demonstrated that cilostazol attenuated AAA development and reduced AAA 
incidence induced by chronic AngII infusion. Furthermore, this inhibitory effect of 
cilostazol on AngII-induced AAA formation was, at least in part, due its 
anti-inflammatory effect to reduce activation of the cAMP-PKA pathway in endothelial 
cells.  
Cilostazol is used widely as an anti-platelet drug. In addition, cilostazol has 
been reported to have many pleiotropic effects including anti-inflammatory, 
anti-proliferative and vasodilatory. Previous studies have shown that cilostazol 
inhibited vascular inflammation by downregulation of VCAM-1 expression in a diabetic 
rat model27, and attenuated MCP-1 and MMP-9 expression in a balloon-injury model28 
in vivo.  Cilostazol exerted anti-inflammatory effects by reducing MCP-1 production 
in vitro44, TNF-α production induced by lipopolysaccharide stimulation45, NF-kB 
activation and VCAM-1 expression46.  Genetic depletion of cyclooxygenase-2 and 
osteopontin (Spp1) attenuated AngII-induced AAA formation, indicating these 
molecules play pivotal role in development of AAA14, 16.   Consistent with these 
previous studies, in our study, gene expression of Ccl2/Mcp-1, Il-1β, Cox2, Spp1 were 
reduced in the aortic wall during cilostazol administration, resulting in AAA 
attenuation. 
 The AngII-induced AAA model provides similar features found in human AAA 
including medial degeneration, inflammation, intraluminal thrombus, rupture and 
atherosclerosis11. However, AngII-induced AAAs are formed in the suprarenal aorta, 
which differs in location from human AAAs. In other AAA models, the elastase infusion 
model and CaCl2 model induces AAA in infra-renal aorta.  Zhang et al. reported that 
cilostazol retarded AAA development by inhibiting MMP activities, expression of 
NF-κB and oxidative stress using rat elastase AAA model47. Taken together, cilostazol 
may provide a new therapeutic option for AAA. 
During development of AngII-induced AAA, an initial event is medial 
accumulation of macrophages, which may lead to subsequent medial rupture7.  We 
investigated how cilostazol prevented vascular inflammation induced by AngII infusion.  
First, we investigated PDEIII localization in the murine aortic wall.  PDEIII was 
reported previously to be localized in vascular smooth muscle cells, endothelium, and 
activated macrophages21, 23, 48.  In our study, PDEIII was localized mainly in 
endothelial cells.  Accordingly, we investigated the effect of cilostazol on endothelial 
cells using murine primary cultured aortic endothelial cells.  In vascular endothelium, 
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cilostazol has been reported previously to increase NO synthesis49 to exert 
anti-inflammatory effects including reduction of monocyte chemoattractant protein-1 
secretion44 and VCAM-1 expression46.  Furthermore, it is well established that 
increases in intracellular cAMP promote endothelial barrier integrity43.  We confirmed 
that cilostazol reduced expression of adhesion molecules and the production of 
inflammatory cytokines, thereby reducing the endothelial response to inflammation.  
Given these findings, we conclude that cilostazol, in part, reduced macrophage 
accumulation into the media through activation of the cAMP-PKA pathway in 
endothelial cells.  
Matrix metalloproteinases are increased in aortic tissue from AAA patients50-52.  
Thus, these proteinases were considered to exert a pivotal role in aneurysm formation.  
In AngII-induced AAA, both MMP-2 and MMP-9 are also activated, and are thought to 
be important for AAA development53. Genetic disruption of MMP-9 has been reported 
to suppress elastase induced AAA54. Inhibition of MMP-2 also has been reported to 
attenuate AAA formation in CaCl2 induced AAAs55.  A previous experimental study 
using elastase induced AAA model revealed cilostazol reduced MMP-2 and MMP-9 
activities in the aortic wall47.  In our study, cilostazol administration suppressed 
AngII-induced MMP activity and thereby prevented matrix protein degradation and 
protected the structural integrity of the aorta. 
Although AngII promotes atherosclerosis as well as aneurysms in 
hypercholesterolemic mice 7, the occurrence and degree of severity varies in previous 
reports 36,38,56,57.  Indeed, atherosclerosis and AAA can respond differently to specific 
interventions7, 20, 36,38,56,57. These findings imply that the mechanisms underlying 
atherosclerosis and aneurysms are different. In previous studies, cilostazol reduced 
atherosclerosis in low-density lipoprotein receptor -/- mice58 and apoE -/- mice59 fed a 
high-fat diet.  However, in our study, cilostazol had no effect on AngII-accelerated 
atherosclerosis in the aortic arch.  
AngII infusion also induces AAAs in normolipidemic mice, but the incidence is 
3-4 fold lower than in hyperlipidemic mice60.  However, there is only weak evidence 
correlating total cholesterol concentrations and aneurysmal growth in humans61, 62.  
In the AngII model, concentrations of plasma apolipoprotein B-containing lipoproteins 
are more important to AAA formation than HDL-cholesterol63. Treatments with statin or 
Omega 3 poly unsaturated fatty acids have a certain effect on aneurysm development 
and growth64, 65.  Both animal and clinical studies have shown that cilostazol 
decreases concentrations of serum triglyceride and increases high-density 
lipoprotein24.  However, in our study, cilostazol had no effect on serum lipid 
concentrations, implying that cilostazol attenuated AAA through other 
pharmacological effects. Additionally, this finding was consistent with no improvement 
of atherosclerosis by cilostazol administration. 
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Several clinical studies reported that blood pressure is considered as an 
important player in AAA formation and growth66.  Several animal studies have 
indicated that propranolol, a β-blocker, might attenuate aneurysmal growth on the 
bases of its hemodynamic properties and its biochemical effect on matrix 
cross-linkage67, 68.  However, clinical studies failed to show the efficacy of propranolol 
on aneurysmal expansion.  On the other hand, cilostazol sometimes causes 
tachycardia in clinical situations.  In our animal study, cilostazol had no effect on 
blood pressure and pulse rate. It is likely that pulse rate may not influence AAA 
formation and growth. 
There are several reports regarding usefulness of other anti-platelet therapy on 
AAA development and progression69-71.  Owens et al. reported platelet inhibitors, 
aspirin and clopidogrel reduced death from AAA rupture but had no effect on dilatation 
of abdominal aorta in established AngII-induced AAAs.  Furthermore, they also 
showed that administration of aspirin and P2Y12 inhibitors were associated with 
reduced death in AAA patients in a human retrospective study72.  Since cilostazol 
exerts its anti-platelet effect in a mechanism different from that of aspirin and 
clopidogrel, it may offer a beneficial effect on the reduction of aortic dilation in an 
established AAA model.  However, further studies are warranted to test and clarify 
the effect of cilostazol regarding the aspect of anti-platelet effect on established AAA 
growth and rupture. 
 
Conclusion 
 
Cilostazol attenuated AngII-induced AAA formation by reducing inflammatory 
changes in the aortic wall.  Cilostazol exerted this anti-inflammatory effect through 
PDEIII inhibition in aortic endothelial cells.  Cilostazol could be a therapeutic agent 
for abdominal aortic aneurysms. 
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Supplemental Table I. Characteristics of Mice 
 
Study Groups 
N 
Body 
Weight (g) 
Systolic 
Blood 
Pressure 
(mmHg) 
Pulse Rate 
(bpm)  Treatment 
Saline Vehicle 6 26.9 ± 1.0 98 ± 3 621 ± 34 
 Cilostazol 5 26.1 ± 1.0 97 ± 3 651 ± 21 
AngII Vehicle 16 27.3 ± 0.7 126 ± 24* 600 ± 14 
 Cilostazol 14 27.7 ± 0.6 132 ± 19† 608 ± 15 
 
Body weight, systolic blood pressure and pulse rate were measured at the end of the 
study.  AngII elevated systolic blood pressure in AngII and AngII + cilostazol group 
(*p = 0.004, †p = 0.001 respectively versus saline infused groups) Values are 
represented as mean ± SE.  Statistical analyses were performed by Two Way 
ANOVA. 
 
 
 
 
 
  
Supplemental Table II. Effects of Cilostazol on Plasma Lipid Concentration 
 
Study Groups 
N 
Total 
Cholesterol 
(mg/dl) 
Triglyceride 
(mg/dl) 
HDL- 
Cholesterol 
(mg/dl)  Treatment 
Saline Vehicle 5 484.2 ± 39.8 340.4 ± 45.9 13.0 ± 2.4 
 Cilostazol 5 584.0 ± 23.1 391.0 ± 42.1 17.1 ± 2.9 
AngII Vehicle 16 536.3 ± 29.5 282.0 ± 27.5 17.1 ± 2.1 
 Cilostazol 14 512.7 ± 30.7 304.6 ± 35.7 17.6 ± 1.5 
 
Total cholesterol, triglyceride, HDL-cholesterol concentrations in plasma were 
measured after 16 hour food deprivation at the end of study.  Values are represented 
as mean ± SE.  No statistical differences were seen in values using Two Way 
ANOVA. 
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Figure Legends 
 
Figure 1. Cilostazol attenuated AngII-induced AAA formation. 
A)  AngII infusion significantly increased ex vivo maximal diameters of abdominal 
aortas from AngII and AngII + cilostazol mice (p < 0.001 and p = 0.032, respectively 
when comparing saline infused group); while cilostazol attenuated enlargement of 
aortic diameter (p = 0.049 when comparing the AngII-infused group).  Aortic diameter 
measurements from each mouse are represented by a circle or an inverted triangle 
(black circles represent saline-infused mice without cilostazol administration, white 
circles represent saline-infused mice with cilostazol administration, black triangles 
represent AngII-infused mice without cilostazol administration, white triangles 
represent AngII-infused mice with cilostazol administration, diamonds represent 
means, and bars represent SE.  Statistical analysis was performed by two-way 
ANOVA. 
B)  Representative images of abdominal aortas from experimental mice infused with 
AngII and fed control (left) or cilostazol-containing diets (right).   
C)  The incidence of AAA (> 50% increase in aortic width) was 79% in AngII mice 
(black bar), and was decreased significantly to 43% in AngII + cilostazol mice (white 
bar). Statistical analyses were performed by Fisher’s Exact test (p = 0.029).   
D)  The mortality ratio from AAA rupture in AngII-infused mice is shown in black bars, 
and the mortality ratio in AngII-infused mice administered cilostazol are shown in 
white bars.  There was no significant difference in mortality from aneurysm rupture 
between these two groups by Fisher’s exact test.  
 
 
Figure 2. Cilostazol reduced elastin degradation and macrophage accumulation in the 
aortic media.  
Elastic fibers were stained with Verfoeff’s staining in tissues sections of suprarenal 
aortas (A-F).  A, D, G were samples from saline-infused mice.  B, E, H were 
samples from AngII-infused mice.  C, F, I were samples from AngII-infused + 
cilostazol mice.  
 Disruption of elastic fibers and enlargement of aortic diameters was seen in aortas 
from AngII-infused mice (B, E).  Degradation of elastic fibers and enlargement of 
aortic diameters were reduced in aorta from AngII-infused + cilostazol mice (C, F). 
Representative immunostaining images of macrophages with an anti-mouse CD68 
antibody (G-I).  Macrophages were localized predominantly in the media of 
suprarenal aortas from AngII-infused mice (H), but were only seen rarely in aortas 
from AngII-infused + cilostazol mice (I). * indicates the lumen of aorta, arrow head 
indicates the perimeter of the media. (bar = 200 μm) 
 
 
Figure 3.  Cilostazol reduced enzymatic activity of MMP-2 and -9 in the aorta.  
A)  Gelatin zymography detected MMP-2 and MMP-9 activity in tissue extracts from 
aortas (n = 3, each group).  Pro-form MMP-2 was detected in the murine aorta 
without neither AngII nor cilostazol administration.  Pro-form and active-form of 
MMP-2 (72 and 59 kDa), MMP-9 (92 kDa) were detected in AngII-infused mice.  
Activities of MMP-2 and MMP-9 were reduced in aortas from AngII + cilostazol mice.  
Cilostazol diminished AngII-induced MMP-2 and MMP-9 activation. 
B)  Quantitative data for MMP-2 and MMP-9 activity.  Each bar represents the mean 
enzymatic activity of MMP-2 (top graph) or MMP-9 (bottom graph) in aortas from 
saline mice (gray bar), AngII mice (black bar), and AngII + cilostazol mice (white bar).  
AngII-infusion increased MMP-2 and MMP-9 activity (p = 0.005, p = 0.011 when 
compared to saline-infused mice, respectively); cilostazol reduced the abundance (p = 
0.006, p = 0.045).  Statistical analysis was performed by One Way ANOVA. 
 
Figure 4.  Cilostazol reduced relative mRNA abundance of inflammatory cytokines 
and MMPs in aortas.  
Aortas were harvested after 1 week of AngII infusion, with or without cilostazol (n 
= 5-7).  Each bar shows relative gene expression normalized to 18S in saline mice 
(gray bar), AngII-infused mice (black bar), and AngII-infused + cilostazol mice (white 
bar).   These inflammatory cytokines and MMPs were elevated in aortas from 
AngII-infused mice, but were reduced by cilostazol administration.  Statistical 
analyses were performed by One Way ANOVA.  
 
Figure 5. Cilostazol reduced mRNA abundance of inflammatory cytokines and 
adhesion molecules in cultured aortic endothelial cells isolated from apoE -/- mice.  
A)  mRNA abundance of Ccl2/Mcp-1 and Icam-1 were increased by TNF-α 
incubation (1 ng/ml, 24 hours), but suppressed by cilostazol (1 μM, 10 μM) in a 
concentration-dependent manner (n = 3 in each group). Statistical analyses were 
performed by One Way ANOVA. 
B)  Quantitative mRNA abundance of inflammatory cytokines and adhesion 
molecules in aortic endothelial cells (n = 3 in each group).  Expression of Ccl2/Mcp-1, 
Icam-1 and Vcam-1 were upregulated by TNF-α stimulation (black bar), and were 
significantly reduced by cilostazol incubation (white bar). Statistical analyses were 
performed by One Way ANOVA.  
C)  CCL2/MCP-1 concentrations in culture medium were measured by using a 
commercial ELISA kit.  Aortic endothelial cells from apoE -/- mice were incubated 
with the indicated conditions for 24 hours.  Cilostazol (10 μM) administration reduced 
CCL2/MCP-1 in culture medium. Statistical analyses were performed by One Way 
ANOVA. 
D)  ICAM-1 expression in aortic endothelium was evaluated by Western blotting (n = 
3 in each group). The relative abundance of ICAM-1 protein was quantified by 
densitometry and normalized to the abundance under the control condition. Statistical 
analyses were performed by One Way ANOVA.  
 
Figure 6.  Cilostazol suppressed Ccl2/Mcp-1 and Icam-1 
mRNA abundancethrough the cAMP-PKA pathway in aortic endothelial cells 
isolated from apoE -/- mice. Aortic endothelial cells were incubatedwith indicated 
conditions (n = 3 in each group).  The effects of cilostazol were mimicked by forskolin 
(10 μM), an activator of adenylate cyclase, and were abrogated by H89 (10 μM), an 
inhibitor of PKA.  Statistical analysis was performed by One Way ANOVA. 
 
 
 
Cilostazol － ＋ － ＋
Supplemental Figure I.
Supplemental Figure I. Cilostazol did not reduce atherosclerosis induced by AngII infusion.
While AngII infusion significantly increased en face atherosclerosis area, cilostazol had no 
effect on lesion areas.  Values for each individual mouse is represented by a circle or an 
inverted triangle (closed circle represents saline-infused mice, closed circle represents 
cilostazol mice, closed triangle represents AngII-infused mice, opened triangle represents 
AngII-infused + cilostazol mice); diamonds represent means and bars represent SE.  
Statistical analysis was performed by Two Way ANOVA.
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Supplemental Figure II. Localization of PDEIII in aortic wall
A)  Immunostaining of PDEIII in tissuesections of abdominal aorta from apoE -/- mice, with or 
without AngII-induced AAA.  No positive staining was observed in negative controls (no 
antibody; used neither 1st antibody nor 2nd antibody, 2nd antibody; used only 2nd antibody 
without 1st antibody), PDEIII were expressed mainly in aortic intima (arrow head). (bar = 50 μm)
